Cathepsin K inhibition by VBX1000 alleviates canine periodontitis
The findings support the inhibition of cathepsin K by VBX1000 as a new therapeutic approach for mild-to-moderate periodontal disease in dogs. A randomized, double blinded placebo-controlled trial in dogs should confirm the potential of VBX1000 in this indication.
Authors
- Jerzy Gawor (ORCID: https://orcid.org/0000-0001-9096-5671)
- Paweł Kowalczyk (ORCID: https://orcid.org/0000-0003-4025-3750)
- Alicja Gajosz
- Rémy Hanf
- Daria Ziemann Gawor
- Julien Salindre
- Dominique Tierny
- Isabelle Druet
- Noémie Dam
- Matthieu Dubruque
Institutions
- Université de Bordeaux (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- National Veterinary Research Institute (PL)
- Veolia (France) (FR)
- Centrum Badań i Innowacji Pro-Akademia (PL)
- Clinique Claude-Bernard (FR)
- Instytut Badań Rynku, Konsumpcji i Koniunktur (PL)
Publication Details
- Journal
- Frontiers in Veterinary Science
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fvets.2025.1656782
- Primary Topic
- Oral microbiology and periodontitis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00